Here are eight things to know about the company’s financial report:
1. Operating income increased 8 percent over 2013, mainly from the recognition of grant income.
2. There as a higher operating loss in 2014, mainly from increased research and development investments and administrative expenses.
3. The company progressed two ongoing Phase III trials for PREOB and authorized patient enrollment in five new centers across the United Kingdom.
4. The first clinical trials with the company’s unique allogeneic bone cell therapy ALLOB for delayed-union fractures and spinal fusions was initiated last year.
5. There were positive results in the first four patients in the ALLOB trial by the end of the year in both non-unions and spinal fusion.
6. The company increased the total number of staff last year from 52 people to 72 people, with the majority of hires related to clinical development.
7. Bone Therapeutics strengthened its board of directors with three new independent directors that brought scientific, business development and corporate finance expertise.
8. At the end of the year, Bone Therapeutics had a successful IPO on Euronext Brussels and Euronext Paris.
More articles on orthopedic devices:
10 key trends in the global orthopedic trauma market
Stryker, Aurora Spine, ConforMIS & more—16 key notes
Brainlab introduces new stereotactic radiosurgery planning tools
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
